Loading…
Education
Hosted by Unknown Host · Education · EN · 514 episodes
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
38%
Guest openness
Selective
Sign up to generate a grounded pitch for Oncology Today with Dr Neil Love.
Signup to Generate a PitchOncology Today with Dr Neil Love is a education podcast hosted by Unknown Host, with 514 episodes on record and a Required Pod Score of 80.
Unknown Host hosts Oncology Today with Dr Neil Love, a education show with 514 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #348
Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications
Episode #347
Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56) Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16) Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52) NCPD information and select publications
Episode #346
Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02) Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25) Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43) Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications
Episode #347
Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48) Management of HER2-Positive Gastroesophageal Cancer (25:11) Neoadjuvant Therapy for Gastroesophageal Cancer (45:13) Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial. CME information and select publications
Episode #346
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Therapy (2:48) Relapsed/Refractory Disease (39:30) CME information and select publications
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
